Literature DB >> 15699466

Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia.

Ralf Dechend1, Petra Gratze, Gerd Wallukat, Erdenechimeg Shagdarsuren, Ralf Plehm, Jan-Hinrich Bräsen, Anette Fiebeler, Wolfgang Schneider, Silvia Caluwaerts, Lisbeth Vercruysse, Robert Pijnenborg, Friedrich C Luft, Dominik N Müller.   

Abstract

We used rats transgenic for the human angiotensinogen (hAogen) gene and the human renin (hRen) gene and crossed the strains to produce a model of preeclampsia in the dams. The female (n=9) hAogen x male hRen cross had severe (telemetry-measured) hypertension and albuminuria, which developed during the last trimester of pregnancy and subsided after delivery. The converse cross (n=9) and control (n=9) SD rats did not. We demonstrated that the female hAogen x male hRen cross had agonistic antibodies capable of activating the angiotensin (Ang) II AT1 receptor (AT1R-AA) and defined the epitope on the receptor's second extracellular loop. The phenomenon also occurs in humans with preeclampsia. The rats displayed renal histology reminiscent of preeclampsia, including fibrin deposition confined to the glomeruli. The complement system was activated in glomeruli and IgG deposits were present that may represent AT1R-AA. Finally, we observed an atherosis-like lesion in the spiral arteries of the placental bed, which we called placental-bed arteriolosclerosis. Our model may be relevant to preeclampsia in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699466     DOI: 10.1161/01.HYP.0000154785.50570.63

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  62 in total

1.  17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.

Authors:  Lorena M Amaral; Denise C Cornelius; Ashlyn Harmon; Janae Moseley; James N Martin; Babbette LaMarca
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

3.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

Review 4.  Rat placentation: an experimental model for investigating the hemochorial maternal-fetal interface.

Authors:  M J Soares; D Chakraborty; M A Karim Rumi; T Konno; S J Renaud
Journal:  Placenta       Date:  2012-01-28       Impact factor: 3.481

5.  Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy.

Authors:  Justin Brewer; Ruisheng Liu; Yan Lu; Jeremy Scott; Kedra Wallace; Gerd Wallukat; Janae Moseley; Florian Herse; Ralf Dechend; James N Martin; Babbette Lamarca
Journal:  Hypertension       Date:  2013-09-16       Impact factor: 10.190

Review 6.  Are we getting closer to a Nobel prize for unraveling preeclampsia?

Authors:  Ralf Dechend; Friedrich C Luft
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

7.  Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.

Authors:  Cissy C Zhou; Yujin Zhang; Roxanna A Irani; Hong Zhang; Tiejuan Mi; Edwina J Popek; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia
Journal:  Nat Med       Date:  2008-07-27       Impact factor: 53.440

8.  Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.

Authors:  Babbette LaMarca; Gerd Wallukat; Mayte Llinas; Florian Herse; Ralf Dechend; Joey P Granger
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

9.  Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis.

Authors:  Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne M McGee; Michael Bader; Ralf Dechend; Allyn C Howlett; K Bridget Brosnihan
Journal:  Hypertension       Date:  2014-06-16       Impact factor: 10.190

10.  Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.

Authors:  Jose A Santiago-Font; Lorena M Amaral; Jessica Faulkner; Tarek Ibrahim; Venkata Ramana Vaka; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.